放射损伤肿瘤血管引发促进肿瘤复发的程序
本综述(主要为临床前数据)总结证据表明,放疗相关剂量照射启动一条通路:内皮细胞丢失和灌注减少导致肿瘤缺氧和HIF-1升高,进而增加SDF-1(CXCL12)捕获表达CXCR4的单核/巨噬细胞,使肿瘤相关巨噬细胞M2极化并恢复肿瘤血管,促进肿瘤复发。该通路可被多种抑制剂阻断,并在临床前模型中增强放疗反应、保护正常组织;CXCR4抑制剂plerixafor联合放疗胶质母细胞瘤的首次人体试验显示有希望的局部控制提高。
要点
- 放疗相关剂量照射后肿瘤血管损伤启动HIF-1–SDF-1–CXCR4–TAM通路促进血管重建和复发。
- 抑制单核/巨噬细胞、HIF-1、CXCL12、CXCR4或CSF-1R可在临床前模型增强放疗反应。
- CXCR4抑制剂plerixafor联合放疗胶质母细胞瘤首次人体试验显示局部控制提高。
核心结论
- 放射治疗相关剂量照射对肿瘤血管的损伤启动一条促进肿瘤血管重建并导致肿瘤复发的程序。
- 该程序可被多种通路抑制剂阻断,并在临床前肿瘤模型中稳健增强放疗反应。
- CXCR4抑制剂plerixafor联合放疗胶质母细胞瘤的首次人体试验显示有希望的局部肿瘤控制提高。
研究设计与样本
- 本综述主要汇总临床前数据,总结放射治疗相关剂量照射启动促进肿瘤血管重建通路的证据。
主要发现
- 照射后内皮细胞丢失和肿瘤血流灌注减少导致肿瘤缺氧增加和HIF-1水平升高。
- 肿瘤再氧合产生的活性氧(ROS)也可使HIF-1水平升高。
- HIF-1升高使肿瘤内趋化因子SDF-1(CXCL12)水平增加,捕获表达CXCR4受体的单核/巨噬细胞。
- 肿瘤相关巨噬细胞(TAM)增多并高度促血管生成(M2极化),恢复肿瘤血管并促进肿瘤复发。
- CSF-1R负责TAM的M2极化,是通路阻断靶点之一。
关键数值与推荐
- 阻断该通路的抑制剂包括单核/巨噬细胞抑制剂、HIF-1抑制剂、CXCL12抑制剂、CXCR4抑制剂和CSF-1R抑制剂。
- 上述抑制剂在多种临床前肿瘤模型中均稳健增强放疗反应。
- 同一类抑制剂对多种正常组织的放射损伤提供保护。
- 部分通路抑制剂已可临床使用,CXCR4抑制剂plerixafor联合放疗胶质母细胞瘤的首次人体试验显示有希望的局部肿瘤控制提高。
临床怎么用
- 该通路为放疗联合HIF-1、CXCL12、CXCR4、CSF-1R或单核/巨噬细胞抑制剂提供临床前依据。
- 部分通路抑制剂已临床可用,支持开展进一步临床试验验证放疗联合策略。
- 同一类抑制剂可能同时增强肿瘤放疗反应并保护正常组织放射损伤。
局限性
- 本综述主要基于临床前数据,临床证据有限。
- 仅CXCR4抑制剂plerixafor联合放疗胶质母细胞瘤有首次人体试验结果,仍需进一步临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This review, mostly of preclinical data, summarizes the evidence that radiation at doses relevant to radiation therapy initiates a pathway that promotes the reconstitution of the tumor vasculature leading to tumor recurrence. The pathway is not specific to tumors; it promotes repair of damaged and ischemic normal tissues by attracting proangiogenic cells from the bone marrow. For irradiated tumors the pathway comprises: (1) loss of endothelial cells and reduced tumor blood perfusion leading to increased tumor hypoxia and increased levels of hypoxia inducible factor-1 (HIF-1). Alternatively, increased HIF-1 levels may arise by reactive oxygen species (ROS) production caused by tumor reoxygenation. (2) Increased HIF-1 levels lead to increased levels in the tumor of the chemokine stromal cell-derived factor-1 (SDF-1, CXCL12), which captures monocytes/macrophages expressing the CXCR4 receptor of CXCL12. (3) The increased levels of tumor-associated macrophages (TAMs) become highly proangiogenic (M2 polarized) and restore the tumor vasculature, thereby promoting tumor recurrence. The relevance of this pathway for radiation therapy is that it can be blocked in a number of different ways including by inhibitors of monocytes/macrophages, of HIF-1, of CXCL12, of CXCR4, and of CSF-1R, the latter of which is responsible for the M2 polarization of the TAMs. All of these inhibitors produce a robust enhancement of the radiation response of a wide variety of preclinical tumor models. Further, the same inhibitors actually provide protection against radiation damage of several normal tissues. Some of these pathway inhibitors are available clinically, and a first-in-human trial of the CXCR4 inhibitor, plerixafor, with radiation therapy of glioblastoma has yielded promising results, including an impressive increase in local tumor control. Further clinical trials are warranted.
引用
- Brown JM. Radiation Damage to Tumor Vasculature Initiates a Program That Promotes Tumor Recurrences. Int J Radiat Oncol Biol Phys. 2020. PMID: 32473180. doi:10.1016/j.ijrobp.2020.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。